176 related articles for article (PubMed ID: 37767191)
1. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
Wang ZM; Zhuang RY; Guo X; Zhang CL; You Y; Chen LS; Liu WS; Zhang Y; Luo RK; Hou YY; Lu WQ; Zhou YH
Clin Cancer Res; 2022 Dec; 28(24):5290-5296. PubMed ID: 36228149
[TBL] [Abstract][Full Text] [Related]
3. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
5. First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial.
Li T; Dong Y; Wei Y; Wang S; Liu Y; Chen J; Xiong W; Lin N; Huang X; Liu M; Yan X; Ye Z; Li B
Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38483309
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
7. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
[TBL] [Abstract][Full Text] [Related]
8. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.
Liu G; Feng Y; Li J; Deng T; Yin A; Yan L; Zheng M; Xiong Y; Li J; Huang Y; Zhang C; Huang H; Wan T; Huang Q; Lin A; Jiang J; Kong B; Liu J
EClinicalMedicine; 2022 Dec; 54():101767. PubMed ID: 36583171
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma.
Sun X; Xu J; Xie L; Guo W
Int J Gen Med; 2022; 15():7581-7591. PubMed ID: 36196372
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
Cai M; Zhu J; Zhou G
Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
Front Oncol; 2022; 12():922127. PubMed ID: 35912272
[TBL] [Abstract][Full Text] [Related]
14. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
15. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer.
Huang JY; Xie XF; Chen XL; Zhang QY; Chen LP; Bai X; Lan XF; Song L; Guo JF; Du CW
Front Oncol; 2023; 13():1122294. PubMed ID: 37124484
[TBL] [Abstract][Full Text] [Related]
16. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
Zhu J; Song C; Zheng Z; Xia L; Chen Y; Ke G; Wu X
Front Oncol; 2021; 11():720343. PubMed ID: 34796105
[TBL] [Abstract][Full Text] [Related]
18. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Li N; Wu T; Hong YG; Guo YZ; Cheng YF; Ma YJ; Bie LY; Cui DH; Gao XH; Tan BX; Li BS; Luo SX; Wang JS
BMC Med; 2022 Dec; 20(1):472. PubMed ID: 36482345
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Yan Q; Yao WT; Du XH; Guo LY; Fan YC
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
